We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+60.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.46B
AUM Growth
+$766M
Cap. Flow
-$128M
Cap. Flow %
-3.7%
Top 10 Hldgs %
44.87%
Holding
104
New
18
Increased
30
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$55.7M
2
CELC icon
Celcuity
CELC
+$53M
3
ROIV icon
Roivant Sciences
ROIV
+$50M
4
PEN icon
Penumbra
PEN
+$47.4M
5
MRUS
Merus
MRUS
+$42M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$520M
2
SLNO
Soleno Therapeutics
SLNO
+$36.1M
3
AORT icon
Artivion
AORT
+$29.2M
4
BBNX
Beta Bionics
BBNX
+$23.1M
5
EOLS icon
Evolus
EOLS
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
51
Nurix Therapeutics
NRIX
$2.4B
$13.1M 0.38%
1,416,149
+319,164
+29% +$3.31M
RAPP
52
Rapport Therapeutics
RAPP
$2.04B
$12M 0.35%
+403,923
New +$7.21M
OM icon
53
Outset Medical
OM
$77.9M
$11.8M 0.34%
833,333
– –
NAUT icon
54
Nautilus Biotechnolgy
NAUT
$221M
$10.6M 0.31%
12,594,211
– –
CRVS icon
55
Corvus Pharmaceuticals
CRVS
$1.25B
$10.6M 0.31%
1,438,595
– –
KOD icon
56
Kodiak Sciences
KOD
$2.67B
$10.4M 0.3%
+634,577
New +$5.47M
SEPN
57
Septerna Inc
SEPN
$1.51B
$10.2M 0.29%
541,450
– –
GOSS icon
58
Gossamer Bio
GOSS
$83.2M
$10M 0.29%
+3,812,797
New +$8.4M
KYMR icon
59
Kymera Therapeutics
KYMR
$9.52B
$9.61M 0.28%
169,796
-40,310
-19% -$1.82M
IKT icon
60
Inhibikase Therapeutics
IKT
$331M
$8.78M 0.25%
5,421,568
-10,725
-0.2% -$18.6K
CTNM
61
Contineum Therapeutics
CTNM
$532M
$8.4M 0.24%
714,592
+15,106
+2% +$122K
XENE icon
62
Xenon Pharmaceuticals
XENE
$6.6B
$8.06M 0.23%
200,791
– –
AVR
63
Anteris Technologies
AVR
$823M
$7.67M 0.22%
1,705,130
– –
JANX icon
64
Janux Therapeutics
JANX
$992M
$7.15M 0.21%
292,686
– –
IRD
65
Opus Genetics
IRD
$270M
$7.14M 0.21%
4,325,000
– –
TEM
66
Tempus AI
TEM
$9.42B
$6.86M 0.2%
+85,000
New +$5.95M
DYN icon
67
Dyne Therapeutics
DYN
$3.92B
$6.84M 0.2%
540,444
-1,706,946
-76% -$19.5M
KRYS icon
68
Krystal Biotech
KRYS
$10.5B
$6.18M 0.18%
+35,000
New +$5.24M
BBNX
69
Beta Bionics
BBNX
$770M
$5.52M 0.16%
277,944
-1,315,664
-83% -$23.1M
CBIO
70
Crescent Biopharma
CBIO
$407M
$5.39M 0.16%
453,686
– –
HTFL
71
Heartflow Inc
HTFL
$2.15B
$5.05M 0.15%
+150,000
New +$4.82M
RAPT
72
DELISTED
RAPT Therapeutics
RAPT
$4.74M 0.14%
183,890
– –
PEPG icon
73
PepGen
PEPG
$156M
$3.83M 0.11%
+829,870
New +$1.34M
BLTE
74
Belite Bio
BLTE
$6.02B
$3.68M 0.11%
+49,788
New +$3.27M
SCPH
75
DELISTED
scPharmaceuticals
SCPH
$3.31M 0.1%
583,142
+83,142
+17% +$426K
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Perceptive Advisors held 104 positions worth $3.46B, up 28% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $128M in Q3 2025, closing 12 positions and reducing 19 holdings. Its most notable exit was Soleno Therapeutics, an estimated $36.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Abivax worth $33M.

  • Perceptive Advisors's largest Q3 2025 buy was Abivax: 388,608 shares worth $33M.
  • Perceptive Advisors added most to Travere Therapeutics in Q3 2025, an estimated $55.7M increase.
  • Perceptive Advisors's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $520M.
  • Perceptive Advisors fully exited Soleno Therapeutics in Q3 2025, selling an estimated $36.1M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $3.46B portfolio in Q3 2025.
  • Perceptive Advisors opened 18 new positions and closed 12 in Q3 2025.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $3.46B.

Based on Perceptive Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.